Please try another search
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.
Name | Age | Since | Title |
---|---|---|---|
Lili Fu | 38 | 2022 | Independent Non-Executive Director |
Bin Cheng | 56 | 2022 | Independent Non-Executive Director |
Jumin Sun | 47 | 2018 | Chairman of the Supervisory Committee |
Yuezhen Deng | 43 | 2022 | Independent Non-Executive Director |
Jing Zhang | 40 | 2018 | Senior Director of the R&D Center and Supervisor |
Xiwu Hui | 39 | 2022 | Non-Executive Director |
Hongwei Guo | 55 | 2020 | Non-Executive Director |
Changtao Ji | 35 | 2021 | Supervisor |
Ying Xiao | 36 | 2023 | Employee Representative Supervisor |
Shouwu Xie | 40 | 2022 | Non-Executive Director |
Bin Chen | 62 | 2022 | Independent Non-Executive Director |
Hongfeng Zhou | 54 | 2010 | Non-Executive Director |
Qian Liang | 51 | 2018 | Non-Executive Director |
Qian Yuan | 56 | 2010 | Non-Executive Director |
Fang Liu | 46 | 2016 | Supervisor |
Zhenhai Pang | 49 | 2020 | Non-Executive Director |
Weiguo Dai | 60 | 2022 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review